FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.

被引：3

作者：

Goyal, Lipika

Meric-Bernstam, Funda

Hollebecque, Antoine

Valle, Juan W.

Morizane, Chigusa

Karasic, Thomas Benjamin

Furuse, Junji

He, Yaohua

Soni, Nital

Benhadji, Karim A.

Bridgewater, John A.

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Inst Gustave Roussy, Drug Dev, Villejuif, France

[4] Univ Manchester, Manchester, Lancs, England

[5] Christie NHS Fdn Trust, Manchester, Lancs, England

[6] Natl Canc Ctr, Tokyo, Japan

[7] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA

[8] Dana Farber Canc Inst, Boston, MA 02115 USA

[9] Kyorin Univ, Sch Med, Tokyo, Japan

[10] Taiho Oncol Inc, Princeton, NJ USA

[11] UCL, Canc Inst, London, England

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

108

引用

页数：1